Gartner Ord Shs (IT)
$119.51 0.00 (0.00%)
19:00 EDT IT Stock Quote Delayed 30 Minutes
Previous Close $119.51
Market Cap 10.90B
PE Ratio -192.76
Volume (Avg. Vol.)
Day's Range 119.51 - 119.51
52-Week Range 76.91 - 171.77
Dividend & Yield N/A (N/A)
IT Stock Predictions, Articles, and Gartner Ord Shs News
- From InvestorPlace
- From the Web
If you're looking for a strong consensus from the top names among analysts, these are 10 stocks to buy on their recommendations.
Amazon's retail is the top-line champion, but profit factory AWS is under threat of being squeezed. That would severely limit AMZN stock.
It pays to stay on top of the latest profit opportunities and today's updated Portfolio Grader ratings are the place to start
As software promises a bright future in the year ahead, these 4 software stocks to buy will shine in your portfolio
Why Macy’s Inc (M), Constellation Brands, Inc. (STZ) and Gartner Inc (IT) Are 3 of Today’s Worst Stocks
Macy's (M), Gartner (IT) and Constellation Brands (STZ) never even had a chance of making forward progress on Thursday.
The tech sector has several promising stocks to choose from. We've picked five tech stocks that have lots of room to run in 2017
From Seeking Alpha
Eisai (OTCPK:ESALF), in collaboration with Alzheimer's Clinical Trials Consortium and Biogen (NASDAQ:BIIB), has initiated a new global Phase 3 clinical study (AHEAD 3-45) with BAN2401, an anti-amyloid beta (Aβ) protofibril antibody.The study will evaluate the therapeutic effect of BAN2401 on the progression of Alzheimer's disease in individuals in preclinical (asymptomatic) stages of the disease.The AHEAD 3-45 program consists of two trials, A3 and A45, which aim to evaluate the potential of BAN2401 to reduce accumulation of harmful amyloid beta aggregates in the brain and prevent cognitive decline.A total of 1400 participants will be enrolled in the study.
From Analyst Ratings
In a report issued on July 8, Matt Phipps from William Blair maintained a Hold rating on Biogen (BIIB – Research Report). The company’s shares closed last Friday at $277.41. According to TipRanks.com, Phipps is a 4-star analyst with an average return of 14.3% and a 56.6% success rate. Phipps covers the Healthcare sector, focusing
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio